A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density

Journal of Bone and Mineral Research

Volumn 30, Issue 2, 2015, Pages 216-224

  Recker, Robert R ^a   Benson, Charles T ^b   Matsumoto, Toshio ^c   Bolognese, Michael A ^d   Robins, Deborah A ^b   Alam, Jahangir ^b   Chiang, Alan Y ^b   Hu, Leijun ^b   Krege, John H ^b   Sowa, Hideaki ^e   Mitlak, Bruce H ^b   Myers, Stephen L ^b  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

^d Bethesda Health Research Center   (United States)

^e Lilly Research Laboratories Japan   (Japan)

Author keywords

Anabolics; Blosozumab; Bone mineral density; Osteoporosis treatment; Sclerostin antibody

Indexed keywords

ALKALINE PHOSPHATASE; BLOSOZUMAB; CALCIUM; PLACEBO; SCLEROSTIN; VITAMIN D; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; MONOCLONAL ANTIBODY; SOST PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEMUR NECK; HIP; HUMAN; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; LUMBAR SPINE; MULTICENTER STUDY; OSSIFICATION; OSTEOLYSIS; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SPINE; BONE REMODELING; CLINICAL TRIAL; DRUG EFFECTS; GENETIC MARKER; IMMUNOLOGY; METABOLISM; OSTEOPOROSIS, POSTMENOPAUSAL; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; DOUBLE-BLIND METHOD; FEMALE; GENETIC MARKERS; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PLACEBOS; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 84921809759     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2351     Document Type: Article

References (36)

1. International Osteoporosis Foundation. Epidemiology [Internet]. Nyon, Switzerland: IOF; 2014 [cited 2014 Sep 15]. Available from: http://www.iofbonehealth.org/epidemiology.
2. Kanis JA, McCloskey EV, Johansson H, et al. A reference standard for the description of osteoporosis. Bone. 2008;42:467-75.
3. Baron R, Hesse E. Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab. 2012;97:311-25.
4. [No authors listed]. Consensus Development Conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94(6):646-50.
5. Costa AG, Bilezikian JP. Sclerostin: therapeutic horizons based upon its actions. Curr Osteoporos Rep. 2012;10:64-72.
6. Atkins GJ, Findlay DM. Osteocyte regulation of bone mineral: a little give and take. Osteoporos Int. 2012;23:2067-79.
7. Moester MJC, Papapoulos SE, Lowik CWGM, et al. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int. 2010;87:99-107.
8. Veverka V, Henry AJ, Slocombe PM, et al. Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem. 2009;284:10890-900.
9. Kogawa M, Wijenayaka AR, Ormsby R, et al. Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase. J Bone Miner Res. 2013;28:2436-48.
10. Burgers TA, Williams BO. Regulation of Wnt/β-catenin signaling within and from osteocytes. Bone. 2013;54:244-9.
11. Ma YL, Page T, Zeng QQ, et al. Blosozumab, a humanized monoclonal antibody, and a chimeric rodent monoclonal antibody against sclerostin robustly increase bone formation activity in intact monkeys and ovariectomized rats. J Bone Miner Res. 2012;27(Suppl 1):[Oral presentation at: Annual Meeting American Society for Bone and Mineral Research (ASBMR); 2012 Oct 12-15; Minneapolis, MN, USA; Presentation Number: 1062]. Available from: http://www.asbmr.org/meetings/annualmeeting/AbstractDetail.aspx?aid=580ec783-5e46-4f61-bb0d-0b63f8ee361d.
12. Das S, Sakthiswary R. Bone metabolism and histomorphometry changes in murine models treated with sclerostin antibody: a systematic review. Curr Drug Targets. 2013;14:1667-74.
13. McColm J, Hu L, Womack T, et al. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res. 2014;29:935-43.
14. Benson CT, Robins D, Recker R, et al. Effect of blosozumab on bone mineral density: results of a phase 2 study of postmenopausal women with low bone mineral density. Presented at the European Calcified Tissue Society Conference ECTS 2013, Lisbon, Portugal. Bone Abstracts. 2013;1:OC5.3. DOI: 10.1530/boneabs.01.OC5.3 Available from: http://www.bone-abstracts.org/ba/0001/ba0001oc5.3.htm.
15. Matsumoto T, Robins D, Alam J, et al. Effect of blosozumab on bone mineral density in Japanese and non-Japanese postmenopausal women with low bone mineral density. IBMS Bonekey. 2013; 10: Article number 333. [Presented at the International Bone and Mineral Society/Japan Society of Bone and Mineral Research 2013, Kobe, Japan. Abstract OC902]. Available from: http://www.nature.com/bonekey/knowledgeenvironment/2013/130522/bonekey201367/pdf/bonekey201367.pdf.
16. Lewiecki EM. Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis. Expert Opin Biol Ther. 2011;11:117-27.
17. Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26:19-26.
18. McClung M, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370:412-20.
19. World Medical Assembly. Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. Available from: www.wma.net/en/30publications/10policies/b3/. Accessed October 2, 2013.
20. International Conference on Harmonisation. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice. E6(R1). 10 June 1996. Available from: http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6/E6-R1-Guideline.pdf.
21. Public Clinical Trial Registration. A phase 2 randomized study of LY 2541 546 versus placebo in postmenopausal women with low bone mineral density: an evaluation of the dose response relationship using bone mineral density. Available from: http://clinicaltrials.gov/show/NCT01144377.
22. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434-41.
23. Marcus R, Wang O, Satterwhite J, Mitlak B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res. 2003;18(1):18-23.
24. Mallinckrodt CH, Lane PW, Schnell D, Peng Y, Mancuso JP. Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Inf J. 2008;42:303-19.
25. Searle SR, Speed FM, Milliken GA. Population marginal means in the linear model: an alternative to least squares means. Am Stat. 1980;34(4):216-21.
26. Beighton PH, Hamersma H, Brunkow ME, SOST-related sclerosing bone dysplasias. In: Pagon RA, Adam MP, Bird TD, et al., editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. 2002 Jun 04 [updated 2013 Jan 10; cited 2014 Sep 16]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1228/.
27. van Lierop AH, Hamdy N, van Egmond MJ, Bakker E, Dikkers FG, Papapoulos SE. Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers. J Bone Miner Res. 2013;28:848-54.
28. Glass DA. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8:751-64.
29. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011;6(10):e25900. DOI: 10.1371/journal.pone.0025900.
30. Rossini M, Gatti D, Adami S. Involvement of WNT/B-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int. 2013;93:121-32.
31. Silva I, Branco JC. Rank/Rankl/opg: literature review. Acta Reumatol Port. 2011;36:209-18.
32. Evenepoel E, D'Haese P, Brandenburg V. Romosozumab in postmenopausal women with osteopenia. N Engl J Med. 2014;370(17):1664-5. DOI: 10.1056/NEJMc1402398.
33. Li X, Ominsky MS, Niu Q, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23(6):860-9.
34. National Center for Biotechnology Information. Gene Expression Omnibus public functional genomics data repository. Available from: http://www.ncbi.nlm.nih.gov/geo/.
35. Hamersma H, Gardner J, Beighton P. The natural history of sclerosteosis. Clin Genet. 2003;63:192-7.
36. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548-58.